Relay Therapeutics Inc. (RLAY) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Relay Therapeutics Inc. (RLAY)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

4.37

-0.41 (-8.58%)

At close: Jan 14, 2025, 3:59 PM

4.26

-2.51%

After-hours Jan 14, 2025, 05:54 PM EST

undefined% (undefined)

Bid	4.32
Market Cap	730.63M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.8
PE Ratio (ttm)	-1.56
Forward PE	n/a
Analyst	Buy

Ask	4.47
Volume	1,698,091
Avg. Volume (20D)	2,096,352
Open	4.77
Previous Close	4.78
Day's Range	4.24 - 4.85
52-Week Range	4.00 - 11.16
Beta	undefined

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for pa...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 16, 2020

Employees 294

Stock Exchange NASDAQ

Ticker Symbol RLAY

Website https://www.relaytx.com

Analyst Forecast

According to 10 analyst ratings, the average rating for RLAY stock is "Buy." The 12-month stock price forecast is $19, which is an increase of 335.28% from the latest price.

Buy 90.00%

Hold 10.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Relay Therapeutics Inc. is scheduled to release its earnings on Feb 20, 2025, during market hours.
Analysts project revenue of $6.08M, reflecting a n/a YoY growth and earnings per share of -0.55, making a -17.91% decrease YoY.

Why Price Moved

1 month ago · Source

+12.42%

Relay Therapeutics shares are trading higher after... Unlock content with Pro Subscription

4 months ago · Source

+6.71%

Relay Therapeutics shares are trading are trading higher after HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $18 to $19.

News

3 weeks ago · zacks.com

Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade

Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · zacks.com

After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY)

Relay Therapeutics (RLAY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings ...

1 month ago · zacks.com

Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

1 month ago · zacks.com

Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround